Conceptus(R) to Participate in Three Investor Conferences

        Print
| Source: Conceptus, Inc.

MOUNTAIN VIEW, Calif., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the leading surgery-free permanent birth control method, announced today that Company management is planning to participate in the following investor conferences:

  • Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at The Pierre Hotel in New York, NY. A live webcast of the Company presentation will take place at 3:00 p.m. Eastern time and will be available on the Company's website at www.conceptus.com. When accessing the live webcast, select "Investors" then select "Events and Presentations." An archived replay will be available following the live presentation.
  • Stephens Fall Investment Conference on Wednesday, November 14, 2012 at The New York Palace Hotel in New York, NY. There will be no webcast presentation.
  • 24th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2012 at The New York Palace Hotel in New York, NY. A live webcast of the Company presentation will take place at 11:30 a.m. Eastern time and will be available on the Company's website at www.conceptus.com. When accessing the live webcast, select "Investors" then select "Events and Presentations." An archived replay will be available following the live presentation.

About the Essure® Procedure

The Essure procedure, FDA approved since 2002, is the only surgery-free and hormone-free permanent birth control method that can be performed in the comfort of a physician's office in less than 10 minutes (average hysteroscopic time) without the risks associated with general anesthesia or tubal ligation. Soft, flexible inserts are placed in a woman's fallopian tubes through the cervix without incisions. Over the next three months, the body works with the inserts to form a natural barrier in the fallopian tubes to prevent sperm from reaching the egg. Three months after the Essure procedure, an Essure Confirmation Test is given to confirm that the inserts are in place and that the fallopian tubes are blocked, verifying that the patient can rely on Essure for permanent birth control.

The Essure procedure is 99.83% effective based on five years of follow up with zero pregnancies reported in clinical trials, making it the most effective permanent birth control available. Essure's 10-year commercial data tracks closely with its five-year clinical results, and Essure has been proven and trusted by physicians since 2002. The Essure procedure is covered in the U.S. by most public and private insurance plans and approximately 690,000 women worldwide have undergone the procedure.  

About Conceptus®, Inc.

Conceptus, Inc. is the global leader in the development and commercialization of innovative device-based solutions in permanent birth control. The Company manufactures and markets the Essure Permanent Birth Control System.

Please visit www.essure.com for more information on the Essure procedure. Patients may call the Essure Information Center at 1-877-ESSURE-1 with questions or to find a physician in their area.

The Conceptus, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7961

© 2012 Conceptus, Inc.— All rights reserved.

Investor and Public Relations Contact:
Cindy Klimstra
(650) 962-4032